Poland granted SPC for Galliprant® on May 6, 2020, a veterinary drug product developed and marketed by Elanco Animal Health Inc. (Elanco). The SPC extends the period of exclusive sales rights for Galliprant® until March 1, 2031. Additional SPCs for Galliprant® are currently under examination in several major EU countries. The grant in Poland marks the eighth approval in the EU, following grants received in Italy, Holland, Spain, Germany, France, Ireland, and Greece.
Galliprant® (grapiprant tablets) is a prostaglandin E2 (PGE2) EP4 receptor antagonist for the control of pain and inflammation associated with osteoarthritis in dogs. Elanco is currently marketing Galliprant® in the US and several EU countries.
Supplementary Protection Certificate (SPC)
In major countries around the world, a patent generally expires after 20 years following submission of the patent application. However, the patent exclusivity periods for pharmaceuticals may be extended for a maximum of five years in order to compensate for the time consuming and costly research and development. The SPC grant by Poland for Galliprant® represents a five-year extension of the therapy’s exclusive sales period